{"id":3578,"date":"2025-05-05T23:02:35","date_gmt":"2025-05-05T23:02:35","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/05\/05\/vertex-earnings-miss-trikafta-cystic-fibrosis-pause\/"},"modified":"2025-05-05T23:02:35","modified_gmt":"2025-05-05T23:02:35","slug":"vertex-earnings-miss-trikafta-cystic-fibrosis-pause","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/05\/05\/vertex-earnings-miss-trikafta-cystic-fibrosis-pause\/","title":{"rendered":"STAT+: Vertex reports an earnings miss and pause on cystic fibrosis trial"},"content":{"rendered":"<p>    STAT+: Vertex reports an earnings miss and pause on cystic fibrosis trial<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene therapy for sickle cell disease and a recently launched pain medicine.\u00a0<\/p>\n<p>A \u201ctolerability issue\u201d caused a temporary pause to an early stage study involving a closely watched, inhaled, mRNA-based therapy for cystic fibrosis, the company said.\u00a0<\/p>\n<p>Vertex shares fell 3% in after-hours trading, as investors considered a stock trading near its all-time high with a longer wait for its next leg of growth.\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/05\/05\/vertex-earnings-miss-trikafta-cystic-fibrosis-pause\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein and Jason Mast<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/05\/05\/vertex-earnings-miss-trikafta-cystic-fibrosis-pause\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Vertex reports an earnings miss and pause on cystic fibrosis trial Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene therapy for sickle cell disease and a recently launched pain medicine.\u00a0 A \u201ctolerability issue\u201d caused a temporary [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2563,2176,2155,2564,2565,2152,2566],"tags":[2150],"class_list":["post-3578","post","type-post","status-publish","format-standard","hentry","category-biotech","category-moderna","category-pharma","category-pharmaceuticals","category-rare-disease","category-sickle-cell","category-stat","category-vertex","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/3578"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=3578"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/3578\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=3578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=3578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=3578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}